Harnessing the power of liquid solubilisation technologies
Obtaining suitable formulations for preclinical safety and efficacy studies is often a time consuming and challenging task. This is made especially more difficult for today’s researchers as it is estimated that over 90 % of compounds currently in development experience low aqueous solubility characteristics (< 0.1 mg/mL).
In order to facilitate the development of such compounds, scientists at Kuecept have developed the award winning Solent™ Rapid Formulation Screening Service, which combines years of research in drug solubilisation strategies and technologies, excipient safety profiling and formulation process miniaturisation.
All formulations screened in the Solent™ array are specially designed for each individual client, taking into account the test compound's physico-chemical properties (crystallinity, LogP/D, pKa etc), desired administration route, target species and dosing protocol. The ensures formulations identified are safe and robust for all of your preclinical dosing needs.
For more information on this Rapid Formulation Service, please click here.